VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$294.52

Market cap

$75.53B

P/E Ratio

23.62

Dividend/share

N/A

EPS

$12.47

Enterprise value

$67.68B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The EPS has surged by 62% year-on-year and by 30% since the previous quarter
Vertex Pharmaceuticals's net income has surged by 60% YoY and by 30% QoQ
Vertex Pharmaceuticals's quick ratio has decreased by 5% QoQ

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
256.46M
Market cap
$75.53B
Enterprise value
$67.68B
Valuations
Price to earnings (P/E)
23.62
Price to book (P/B)
6.31
Price to sales (P/S)
9.03
EV/EBIT
16.95
EV/EBITDA
16.38
EV/Sales
8.1
Earnings
Revenue
$8.35B
EBIT
$3.99B
EBITDA
$4.13B
Free cash flow
$3.79B
Per share
EPS
$12.47
Free cash flow per share
$14.8
Book value per share
$46.66
Revenue per share
$32.63
TBVPS
$55.46
Balance sheet
Total assets
$15.58B
Total liabilities
$3.65B
Debt
$847.3M
Equity
$11.93B
Working capital
$8.95B
Liquidity
Debt to equity
0.07
Current ratio
4.5
Quick ratio
4.14
Net debt/EBITDA
-1.9
Margins
EBITDA margin
49.5%
Gross margin
88.1%
Net margin
38.3%
Operating margin
48.2%
Efficiency
Return on assets
22.9%
Return on equity
30.1%
Return on invested capital
102.3%
Return on capital employed
30.7%
Return on sales
47.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.81%
1 week
2.25%
1 month
1.56%
1 year
51.18%
YTD
34.12%
QTD
4.52%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$8.35B
Gross profit
$7.36B
Operating income
$4.02B
Net income
$3.19B
Gross margin
88.1%
Net margin
38.3%
The operating income has surged by 77% year-on-year and by 37% since the previous quarter
Vertex Pharmaceuticals's net income has surged by 60% YoY and by 30% QoQ
The operating margin has increased by 42% YoY and by 31% QoQ
VRTX's net margin is up by 29% YoY and by 24% QoQ

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
23.62
P/B
6.31
P/S
9.03
EV/EBIT
16.95
EV/EBITDA
16.38
EV/Sales
8.1
The EPS has surged by 62% year-on-year and by 30% since the previous quarter
The price to earnings (P/E) is 57% less than the 5-year quarterly average of 54.6
The stock's price to book (P/B) is 39% less than its 5-year quarterly average of 10.3 but 11% more than its last 4 quarters average of 5.7
The equity has grown by 30% YoY and by 9% from the previous quarter
The price to sales (P/S) is 27% less than the 5-year quarterly average of 12.3 but 16% more than the last 4 quarters average of 7.8
VRTX's revenue is up by 25% YoY and by 5% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital rose by 41% year-on-year and by 37% since the previous quarter
VRTX's return on assets is up by 36% year-on-year and by 22% since the previous quarter
The return on equity has grown by 32% year-on-year and by 22% since the previous quarter
The return on sales has increased by 30% since the previous quarter and by 29% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 27% YoY and by 9% QoQ
The total liabilities has increased by 21% YoY and by 9% QoQ
VRTX's debt is 93% lower than its equity
The equity has grown by 30% YoY and by 9% from the previous quarter
The debt to equity fell by 30% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.